XML 72 R47.htm IDEA: XBRL DOCUMENT v3.25.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Revenue and Gross Accounts Receivable By Major Customer (Details) - Customer Concentration Risk
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
% of Total Gross Revenues | Fresenius Medical Care Rx      
Concentration Risk [Line Items]      
Concentration risk percentage 30.00% 48.00% 40.00%
% of Total Gross Revenues | U.S. Renal Care      
Concentration Risk [Line Items]      
Concentration risk percentage 29.00%    
% of Total Gross Revenues | DaVita, Inc.      
Concentration Risk [Line Items]      
Concentration risk percentage 25.00%    
% of Total Gross Revenues | Cencora, Inc.      
Concentration Risk [Line Items]      
Concentration risk percentage   19.00% 21.00%
% of Total Gross Revenues | McKesson Corporation      
Concentration Risk [Line Items]      
Concentration risk percentage   12.00% 11.00%
% of Total Gross Revenues | Cardinal Health, Inc.      
Concentration Risk [Line Items]      
Concentration risk percentage     10.00%
% of Gross Accounts Receivable | Fresenius Medical Care Rx      
Concentration Risk [Line Items]      
Concentration risk percentage   42.00%  
% of Gross Accounts Receivable | U.S. Renal Care      
Concentration Risk [Line Items]      
Concentration risk percentage 42.00%    
% of Gross Accounts Receivable | DaVita, Inc.      
Concentration Risk [Line Items]      
Concentration risk percentage 29.00% 16.00%  
% of Gross Accounts Receivable | Cencora, Inc.      
Concentration Risk [Line Items]      
Concentration risk percentage   13.00%